Biomarkers for Lung Cancer Treatment
Author Information
Author(s): Pallis A G, Fennell D A, Szutowicz E, Leighl N B, Greillier L, Dziadziuszko R
Primary Institution: University General Hospital of Heraklion
Hypothesis
Can molecular biomarkers predict the response of non-small-cell lung cancer patients to anti-EGFR treatment?
Conclusion
EGFR mutation status is the strongest predictor for selecting NSCLC patients for first-line treatment with EGFR inhibitors.
Supporting Evidence
- EGFR mutations are linked to better responses to EGFR inhibitors.
- High EGFR gene copy number is associated with improved survival in some studies.
- Immunohistochemistry results for EGFR can vary in predictive value.
Takeaway
Doctors can use certain tests to find out if lung cancer patients will respond well to specific treatments, helping them choose the best medicine.
Methodology
The study involved a bibliographic search of Medline and manual searches of meeting abstracts to gather data on biomarkers in NSCLC.
Potential Biases
Potential biases exist due to the retrospective nature of some analyses and the variability in study designs.
Limitations
The predictive value of some biomarkers was not confirmed in all studies, and results may be biased due to retrospective analyses.
Participant Demographics
The study included various populations, including Asian patients and those from multiple clinical trials.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 0.10–0.25
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website